Nicole H nhassoun at binghamton.edu
Fri Jun 19 13:24:57 PDT 2015

Dear all,

I believe GHI might help estimate that data for CM for 2010 - so let us
know if you'd like to take a look (of course, we also estimate the health
impact of CM). Though, I expect you might really want to do a regression to
figure out the impact of the licensing policies on impact.

All best, -Nicole

On Fri, Jun 19, 2015 at 1:22 PM, Jamie Love <james.love at keionline.org>

> This is the Lilly web page for social media on "increasing access to
> medicine."
> One of the points is that Lilly says it "does not does not seek patents in
> least developed countries (LDCs), as defined by the United Nations. As a
> result, generics manufacturers are free to produce and provide generic
> versions of our medicines in these countries."
> Not surprisingly, they also oppose reference pricing, as a disincentive for
> tiered pricing " based on a purchaser’s ability to pay."
> How well does the Lilly tiered pricing work?  Who knows.  But one way to
> find out is to see what percent of patients who would benefit a drug get
> the drug, in different countries of different incomes.
> Jamie
> http://www.lilly.com/Responsibility/access-to-medicines/Pages/increasing-access-to-medicines.aspx
> Differential Pricing
> Lilly strives to engage with governments throughout the world to offer our
> products at sustainable prices that are affordable for local populations.
> Prices for prescription medicines, like other products, can differ from
> country to country because of differences in currency value and market
> dynamics—or they may be kept artificially low by government price controls.
> We recognize that, for individuals, the price of medicines can present a
> barrier to those who might benefit from them, both in developed and
> emerging markets. Pricing is one way pharmaceutical companies, including
> Lilly, can enhance access to medicines.
> Lilly believes differential pricing can help balance the desire to have
> affordable prices for low-income populations with rewards for innovation.
> We believe that providing financial incentives for pharmaceutical
> innovation is in everyone’s interest. Our ability to improve outcomes for
> individual patients depends on our discovering, developing, and
> commercializing innovative new pharmaceutical products. The profits we
> generate enable us to invest in the research necessary to bring the next
> generation of new medicines to the market.
> Lilly advocates for policies that support differential pricing—i.e., the
> charging of different prices based on a purchaser’s ability to pay.
> Currently, many countries reference the price of medicines in other
> countries as a basis for setting prices for new drugs. This practice limits
> differential pricing because a discounted price in a lower-income country
> can be referenced by a higher-income country. Entering into commercial
> contracts with payers can support the increased use of differential
> pricing, if those contracts are private and the discounted price cannot be
> referenced. Lilly also supports efforts to decrease the final price of
> medicine to patients, such as through minimizing value-added taxes and
> markups applied in the supply chain. Finally, Lilly advocates for stronger
> anti-counterfeiting protections, to ensure patients receive quality-assured
> medicines.
> Patents in Least Developed Countries
> In many developing countries, Lilly does not seek nor enforce patents for
> our medicines, to further contribute to making these medicines more
> accessible. For example, Lilly does not seek patents in least developed
> countries (LDCs), as defined by the United Nations. As a result, generics
> manufacturers are free to produce and provide generic versions of our
> medicines in these countries.
> --
> James Love.  Knowledge Ecology International
> http://www.keionline.org/donate.html
> KEI DC tel: +1.202.332.2670, US Mobile: +1.202.361.3040, Geneva Mobile:
> +41.76.413.6584, twitter.com/jamie_love
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org

Nicole Hassoun
Associate Professor
Binghamton University
Department of Philosophy
4400 Vestal Parkway East
Box 6000
Binghamton, NY 13902-6000
Website: http://harvey.binghamton.edu/~nhassoun/faculty-hassoun.php

More information about the Ip-health mailing list